AMGN vs. RPRX: Amgen vs. Royalty Pharma Stock Comparison

Company Profile

Amgen (AMGN) and Royalty Pharma (RPRX) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AMGN is classified in Biotechnology while RPRX is classified in Pharmaceuticals.

Amgen (AMGN) has more than two decades of public-market history since June 17, 1983, whereas Royalty Pharma (RPRX) listed on June 16, 2020 and has a much shorter record to draw on.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Amgen (AMGN) at 78.35% and Royalty Pharma (RPRX) at 12.09% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Both Amgen (AMGN) at 24.14% and Royalty Pharma (RPRX) at 25.70% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Both Amgen (AMGN) at 35.79% and Royalty Pharma (RPRX) at 81.32% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Amgen (AMGN) at 9.95% and Royalty Pharma (RPRX) at 5.06% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Amgen (AMGN) at 88.23% sits in the top EPS growth quartile, while Royalty Pharma (RPRX) at 23.09% is closer to the peer norm — faster per-share earnings growth for AMGN.

Growth Metrics

Financial Strength

Both Amgen (AMGN) at 1.48 and Royalty Pharma (RPRX) at 1.29 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both balance sheets lean debt-heavy versus peers, but AMGN is more stretched: Royalty Pharma (RPRX) at 0.88 sits in the higher-leverage quartile and Amgen (AMGN) at 3.76 is above its industry benchmark range.

Financial Strength Metrics

Dividends

Both Amgen (AMGN) at 2.16% and Royalty Pharma (RPRX) at 1.37% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Both Amgen (AMGN) at 57.62% and Royalty Pharma (RPRX) at 60.46% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

Dividend Metrics

Valuation

Amgen (AMGN) at 26.69 is near its industry’s usual P/E ratio, while Royalty Pharma (RPRX) at 43.99 sits in the richer quartile — RPRX needs stronger growth or earnings quality to justify the premium.

On P/S ratio, both Amgen (AMGN) at 6.40 and Royalty Pharma (RPRX) at 14.79 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Royalty Pharma (RPRX) at 4.39 sits near its industry’s typical P/B ratio, while Amgen (AMGN) at 17.35 prices above its benchmark range — AMGN looks rich relative to book.

Valuation Metrics